BR112012019534A2 - composição, métodos para preparar uma composição, e para selecionar anticorpos, e, kit - Google Patents

composição, métodos para preparar uma composição, e para selecionar anticorpos, e, kit

Info

Publication number
BR112012019534A2
BR112012019534A2 BR112012019534A BR112012019534A BR112012019534A2 BR 112012019534 A2 BR112012019534 A2 BR 112012019534A2 BR 112012019534 A BR112012019534 A BR 112012019534A BR 112012019534 A BR112012019534 A BR 112012019534A BR 112012019534 A2 BR112012019534 A2 BR 112012019534A2
Authority
BR
Brazil
Prior art keywords
composition
methods
preparing
natural
kit
Prior art date
Application number
BR112012019534A
Other languages
English (en)
Other versions
BR112012019534B1 (pt
Inventor
Idica Adam
Deng Chun-Tsan
I Terasaki Paul
Original Assignee
One Lambda Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by One Lambda Inc filed Critical One Lambda Inc
Publication of BR112012019534A2 publication Critical patent/BR112012019534A2/pt
Publication of BR112012019534B1 publication Critical patent/BR112012019534B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125—Digestion or removing interfering materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

composição, métodos para preparar uma composição, e para selecionar anticorpos, e, kit. são aqui fornecidos as composições que compreendem antígenos de leucócito humano naturais e desnaturados (hla) e métodos de preparar as ditas composições. são também aqui fornecidos os métodos e kits para a detecção de anticorpos para hlas naturais. os hlas naturais são de longe o principal componente das composições, que são preparadas enriquecendo os hlas naturais em uma composição mista por meio das reações enzimáticas seletivas.
BR112012019534-4A 2010-02-17 2011-02-16 Método para preparar uma composição que compreende pelo menos 90% de antígenos de leucócito humano naturais e no máximo 10% de antígenos de leucócito desnaturados BR112012019534B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33825810P 2010-02-17 2010-02-17
US61/338,258 2010-02-17
PCT/US2011/025060 WO2011103172A1 (en) 2010-02-17 2011-02-16 Compositions and methods for the detection of antibodies to native human leukocyte antigen

Publications (2)

Publication Number Publication Date
BR112012019534A2 true BR112012019534A2 (pt) 2018-03-13
BR112012019534B1 BR112012019534B1 (pt) 2021-07-20

Family

ID=43881180

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012019534-4A BR112012019534B1 (pt) 2010-02-17 2011-02-16 Método para preparar uma composição que compreende pelo menos 90% de antígenos de leucócito humano naturais e no máximo 10% de antígenos de leucócito desnaturados

Country Status (8)

Country Link
US (2) US8927290B2 (pt)
EP (2) EP3435083B1 (pt)
JP (2) JP5779599B2 (pt)
CN (1) CN102770448B (pt)
AU (1) AU2011218228B2 (pt)
BR (1) BR112012019534B1 (pt)
CA (1) CA2782448C (pt)
WO (1) WO2011103172A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103172A1 (en) * 2010-02-17 2011-08-25 One Lambda, Inc. Compositions and methods for the detection of antibodies to native human leukocyte antigen
WO2018183779A1 (en) * 2017-03-30 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Multiplex isotype-specific antibody detection
FR3088719B1 (fr) * 2018-11-16 2023-03-31 Commissariat Energie Atomique Procede de preparation d'un echantillon a analyser obtenu a partir de matrice alimentaire
US10836790B1 (en) * 2019-09-20 2020-11-17 Plasma Technologies, Llc Therapeutic protein compositions and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156062A1 (en) * 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
CN1423130A (zh) * 2002-04-26 2003-06-11 帕弗瑞生物技术(北京)有限公司 流式测定固定补体抗体的hla交叉配型方法和试剂盒
AU2003270876A1 (en) * 2002-09-24 2004-04-19 Rico Buchli Anti-hla assay and methods
DE102004019803A1 (de) * 2004-04-23 2005-11-10 Imusyn Gmbh & Co.Kg Verfahren zur Herstellung löslicher MHC-Proteine
GB2442048B (en) * 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
WO2009006312A1 (en) * 2007-07-03 2009-01-08 One Lambda Methods of detecting antibodies specific for denatured hla antigens
WO2011103172A1 (en) * 2010-02-17 2011-08-25 One Lambda, Inc. Compositions and methods for the detection of antibodies to native human leukocyte antigen

Also Published As

Publication number Publication date
AU2011218228A1 (en) 2012-06-28
WO2011103172A1 (en) 2011-08-25
EP3435083B1 (en) 2023-05-24
CA2782448A1 (en) 2011-08-25
JP2013519902A (ja) 2013-05-30
EP2536751B1 (en) 2018-09-12
AU2011218228B2 (en) 2015-05-28
BR112012019534B1 (pt) 2021-07-20
US8927290B2 (en) 2015-01-06
US20150111783A1 (en) 2015-04-23
US9354238B2 (en) 2016-05-31
EP3435083A1 (en) 2019-01-30
US20110201026A1 (en) 2011-08-18
EP2536751A1 (en) 2012-12-26
JP5779599B2 (ja) 2015-09-16
JP2015211691A (ja) 2015-11-26
CN102770448B (zh) 2016-11-16
CA2782448C (en) 2019-04-16
CN102770448A (zh) 2012-11-07

Similar Documents

Publication Publication Date Title
PH12021550083A1 (en) Human anti-tau antibodies
AR089178A1 (es) Anticuerpos anti-il-36r
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
PE20200484A1 (es) Tratamiento para el asma con anticuerpo anti-tslp
BR112016026337A2 (pt) formato biespecífico adequado para o uso na triagem de alto rendimento
MX345092B (es) Anticuerpos anti-tau humanos,.
BR112015017174A2 (pt) preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico
BR112015030946A8 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
BR122021020829B8 (pt) Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
WO2013006474A3 (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
ECSP13012649A (es) Anticuerpos ANTI-IL-23
CR11319A (es) Proteinas de union a antigeno capaces de unirse a linfopoyetina estromatica timica
CO6420355A2 (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
EP3778917A3 (en) Multispecific antibodies, antibody analogs, compositions, and methods
ECSP11011445A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b
BR112013010993A2 (pt) método para a seleção de lotes de componentes de cultura para serem usados na cultura de uma célula de mamífero que expressa uma proteína de interesse
EA201391523A1 (ru) Композиции и способы для переноса энергии митохондрий аутологичных герминативных клеток
BR112014029174A2 (pt) composição de ativador geopolimérico, composição geopolimérica e método para a preparação de uma composição geopolimérica
BR112014011595A2 (pt) método de cimentação e composição de cimento
MX2015003150A (es) Anticuerpos específicos de polipeptido amiloide de islote humano (hiapp) y sus usos.
BR112012028711A2 (pt) métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit
EA201490024A1 (ru) Наполненные силиконовые композиции, их получение и применение
UA111357C2 (uk) Аналоги епоксіейкозатриєнової кислоти, композиція на їх основі, застосування для лікування захворювань та спосіб зниження гіпертонії та нефротоксичності (варіанти)
EA201490945A1 (ru) Набор, содержащий заменитель сыворотки и лабильные факторы
ATE500503T1 (de) Cd86- und cd80-rezeptorkonkurrenztests

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/02/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.